Healthcare Losers: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), Biota Pharmaceuticals Inc (NASDAQ:BOTA), Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)is developing a treatment for X-linked Hypophosphatemia (XLH) through its drug candidate known as KRN23. If successful, the drug will play an important role in the treatment of XLH because there is currently no existing approved therapy for the medical problem. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) weekly performance is 9.70%. On last trading day company shares ended up $44.77. Analysts mean target price for the company is $73.50. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) distance from 50-day simple moving average is 14.54%.

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that Dr. Kaushik J. Dave, President and CEO of Actinium, will present a corporate update at the 2014 BIO International Convention in San Diego, CA on June 26th, 2014. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) shares fell -10.07% in last trading session and ended the day on $8.84. ATNM its return on assets is -485.10%. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) quarterly performance is 7.94%.

Biota Pharmaceuticals Inc (NASDAQ:BOTA), an anti-infective drug development company, intends to lower its fixed costs and expenses over the next six to nine months. The move will help the company to live another day in the future. The expenses adjustment is expected to help the company align with its revenue reality.

The company expects revenue loss following the loss of a key contract with the government. The U.S. Department of Health and Human Services terminated its 2011 agreement BOTA, which saw the government agency provide about $231 million to support development of various treatments by BOTA. The supported treatments included influenza A and B. Biota Pharmaceuticals Inc (NASDAQ:BOTA) shares moved down -6.00% in last trading session and was closed at $3.29, while trading in range of $3.26-$3.50. Biota Pharmaceuticals Inc (NASDAQ:BOTA) year to date performance is -21.48%.

May 07, 2014 Eleven Biotherapeutics Inc (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced it first quarter 2014 financial results on Thursday, May 15, 2014. Eleven’s management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time on Thursday, May 15, 2014 to discuss the quarterly results and recent business developments. Eleven Biotherapeutics Inc (NASDAQ:EBIO) ended the last trading day at $11.16. Company weekly volatility is calculated as 8.70% and price to cash ratio as 3.36. Eleven Biotherapeutics Inc (NASDAQ:EBIO) showed a negative weekly performance of -0.89%.